Amsurg (AMSG) 10-Q 6 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	895,930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		54,797,634

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 85,883	$ 106,660
Restricted cash and marketable securities	14,435	13,506
Accounts receivable, net of allowance of $188,086 and $167,411, respectively	352,891	337,330
Supplies inventory	21,584	21,406
Prepaid and other current assets	76,513	75,771
Total current assets	551,306	554,673
Property and equipment, net	191,920	189,168
Investments in unconsolidated affiliates	172,826	169,170
Goodwill	3,967,902	3,970,210
Intangible assets, net	1,580,337	1,594,637
Other assets	19,655	21,450
Total assets	6,483,946	6,499,308
Liabilities and Equity
Current portion of long-term debt	20,231	20,377
Accounts payable	26,412	32,561
Accrued salaries and benefits	204,191	202,537
Accrued interest	18,005	30,480
Other accrued liabilities	101,861	119,237
Total current liabilities	370,700	405,192
Long-term debt	2,336,284	2,357,956
Deferred income taxes	706,452	699,498
Other long-term liabilities	$ 99,007	$ 96,183
Commitments and contingencies
Noncontrolling interests – redeemable	$ 174,671	$ 175,732
Equity:
Preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding	166,632	166,632
Common stock, no par value, 120,000 shares authorized, 54,789 and 54,294 shares issued and outstanding, respectively	1,349,877	1,345,418
Retained earnings	810,012	781,413
Total AmSurg Corp. equity	2,326,521	2,293,463
Noncontrolling interests – non-redeemable	470,311	471,284
Total equity	2,796,832	2,764,747
Total liabilities and equity	$ 6,483,946	$ 6,499,308

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 188,086	$ 167,411
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,725,000	1,725,000
Preferred stock, shares outstanding	1,725,000	1,725,000
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	54,789,000	54,294,000
Common stock, shares outstanding	54,789,000	54,294,000

Consolidated Statements Of Earn

Consolidated Statements Of Earnings - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues	$ 818,286	$ 638,197
Provision for uncollectibles	(99,440)	(73,999)
Net revenue	724,678	570,445
Operating expenses:
Salaries and benefits	409,839	302,179
Supply cost	46,963	42,584
Other operating expenses	107,682	90,570
Transaction costs	1,390	1,471
Depreciation and amortization	29,072	22,818
Total operating expenses	594,946	459,622
Net loss on deconsolidations	0	(223)
Equity in earnings of unconsolidated affiliates	6,579	2,651
Operating income	136,311	113,251
Interest expense, net	30,810	30,247
Earnings before income taxes	105,501	83,004
Income tax expense	20,797	14,249
Net earnings	84,704	68,755
Less net earnings attributable to noncontrolling interests	53,841	47,717
Net earnings attributable to AmSurg Corp. shareholders	30,863	21,038
Preferred stock dividends	(2,264)	(2,264)
Net earnings attributable to AmSurg Corp. common shareholders	$ 28,599	$ 18,774
Net earnings per share attributable to common shareholders:
Earnings Per Share, Basic	$ 0.53	$ 0.39
Earnings Per Share, Diluted	$ 0.53	$ 0.39
Weighted average number of shares and share equivalents outstanding:
Basic (in shares)	53,665	47,572
Diluted (in shares)	54,001	47,905
Physician Services [Member]
Provision for uncollectibles	$ (93,608)	$ (67,752)
Net revenue	$ 417,544	$ 286,535

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Mandatory Convertible Preferred Stock [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable (Temporary Equity) [Member]
Balance at Dec. 31, 2014		$ 885,393	$ 166,632	$ 627,522	$ 418,684	$ 2,098,231	$ 184,099
Balance (in shares) at Dec. 31, 2014		48,113,000	1,725,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 68,755			21,038	15,037	36,075	32,680
Issuance of restricted common stock (in shares)		296,000
Cancellation of restricted common stock (in shares)		(6,000)
Stock options exercised		$ 1,746				1,746
Stock options exercised (in shares)		77,000
Stock repurchased	$ (3,700)	$ (3,684)				(3,684)
Stock repurchased (in shares)	(67,000)	(67,000)
Share-based compensation		$ 3,709				3,709
Tax benefit related to exercise of share-based awards		3,317				3,317
Dividends paid on preferred stock				(2,264)		(2,264)
Acquisitions and other transactions impacting noncontrolling interests		144			23,012	23,156	(646)
Distributions to noncontrolling interests, net of capital contributions					(14,564)	(14,564)	(32,544)
Disposals and other transactions impacting noncontrolling interests		(1,877)			2,951	1,074	(130)
Balance at Mar. 31, 2015		$ 888,748	$ 166,632	646,296	445,120	2,146,796	183,459
Balance (in shares) at Mar. 31, 2015		48,413,000	1,725,000
Balance at Dec. 31, 2015	$ 2,764,747	$ 1,345,418	$ 166,632	781,413	471,284	2,764,747	175,732
Balance (in shares) at Dec. 31, 2015		54,294,000	1,725,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 84,704			30,863	17,477	48,340	36,364
Issuance of restricted common stock (in shares)		567,000
Cancellation of restricted common stock (in shares)		(7,000)
Stock options exercised		$ 276				276
Stock options exercised (in shares)	12,667	13,000
Stock repurchased	$ (5,700)	$ (5,688)				(5,688)
Stock repurchased (in shares)	(77,780)	(78,000)
Share-based compensation		$ 7,168				7,168
Tax benefit related to exercise of share-based awards		3,605				3,605
Dividends paid on preferred stock				(2,264)		(2,264)
Acquisitions and other transactions impacting noncontrolling interests		542			(1,233)	(691)	(4)
Distributions to noncontrolling interests, net of capital contributions					(18,688)	(18,688)	(37,866)
Disposals and other transactions impacting noncontrolling interests		(1,444)			1,471	27	445
Balance at Mar. 31, 2016	$ 2,796,832	$ 1,349,877	$ 166,632	$ 810,012	$ 470,311	$ 2,796,832	$ 174,671
Balance (in shares) at Mar. 31, 2016		54,789,000	1,725,000

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net earnings	$ 84,704	$ 68,755
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	29,072	22,818
Amortization of deferred loan costs	2,140	2,074
Provision for uncollectibles	99,440	73,999
Net loss on deconsolidations	0	223
Share-based compensation	7,168	3,709
Excess tax benefit from share-based compensation	(3,605)	(3,317)
Deferred income taxes	6,602	3,334
Equity in earnings of unconsolidated affiliates	(6,579)	(2,651)
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(114,523)	(74,214)
Supplies inventory	(178)	(30)
Prepaid and other current assets	(8,423)	13,842
Accounts payable	(6,108)	(2,526)
Accrued expenses and other liabilities	(11,056)	(7,886)
Other, net	3,119	697
Net cash flows provided by operating activities	81,773	98,827
Cash flows from investing activities:
Acquisitions and related expenses	(2,990)	(126,578)
Acquisition of property and equipment	(15,691)	(14,783)
Maturities of marketable securities	2,240	0
Other	(1,509)	(220)
Net cash flows used in investing activities	(17,950)	(141,581)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	16,197	2,227
Repayment on long-term borrowings and revolving credit facility	(40,332)	(5,213)
Distributions to noncontrolling interests	(56,801)	(47,202)
Proceeds from issuance of common stock upon exercise of stock options	276	1,746
Repurchase of common stock	(5,688)	(3,684)
Other	1,748	2,957
Net cash flows used in financing activities	(84,600)	(49,169)
Net decrease in cash and cash equivalents	(20,777)	(91,923)
Cash and cash equivalents, beginning of period	106,660	208,079
Cash and cash equivalents, end of period	85,883	116,156
Supplemental cash flow information:
Interest payments	41,250	40,043
Income tax paid, net of refunds	$ 8,897	$ (88)

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all normal recurring adjustments, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in AmSurg Corp.'s (Company) Annual Report on Form 10-K for the fiscal year ended December 31, 2015 . Ambulatory Services The Company, through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ambulatory surgery centers (ASCs, surgery centers or centers). All LLCs and LPs are referred to herein as “partnerships” and “partners”, respectively. The Company has variable interests in the partnerships through its equity ownership interests. Each partnership is considered a variable interest entity (VIE) due to its structure as a limited partnership or functional equivalent under Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2015-02 “Consolidations (Topic 810) - Amendments to the Consolidation Analysis,” which was adopted effective January 1, 2016. For those partnerships in which the Company’s ownership interest is 51% or greater, the Company is considered the primary beneficiary. The Company is the primary beneficiary due to 1) ownership interest, operating agreements allowing the Company to govern the day-to-day activities, and the Company’s position as the managing member or general partner and 2) the Company's obligation to absorb losses or the right to receive returns proportionate to its equity interest in the partnerships. For the 23 partnerships in which the Company’s ownership interest is less than 51%, the Company is not deemed the primary beneficiary and therefore those partnerships are not consolidated with the exception of 2 partnerships which are consolidated because the Company holds substantive participation rights and has the obligation to absorb losses or right to receive returns proportionate to its equity interest in the partnerships. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated partnerships. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net earnings attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis. Physician Services The Company, through its wholly-owned subsidiary Sheridan Healthcare, is also a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. The Company focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, the Company is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. The Company also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which the Company has management arrangements. The Company's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned subsidiaries. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “ Consolidations. ” Variable Interest Entities For its PCs and certain of its partnerships, the Company is considered the primary beneficiary of the variable interest entities and consolidates under the Variable Interest Model in ASC 810. The total assets of the VIEs, which are included in the accompanying March 31, 2016 and December 31, 2015 consolidated balance sheets, were $735.3 million and $740.1 million , respectively, and the total liabilities of the VIEs were $299.3 million and $299.0 million , as of March 31, 2016 and December 31, 2015 , respectively. Included in total assets as of March 31, 2016 and December 31, 2015 , respectively, were $174.4 million and $176.8 million of assets which were restricted to use and could only be used to settle the obligations of the VIE. The creditors of the VIE have no recourse to the Company, with the exception of $17.4 million and $21.7 million of debt guaranteed by the Company at March 31, 2016 and December 31, 2015 , respectively. The restricted assets and obligations, which are either restricted for use in the VIE or the creditor did not have recourse to the Company, generally consisted of the portion of assets and liabilities attributable to the Company's non-controlling partners. The Company also has certain equity interests in unconsolidated affiliates which meet the definition of a variable interest entity. The Company has a variable interest in these investments through its equity interests; however, the Company is not the primary beneficiary of these entities as it only holds 50% or less of the voting rights and does not have the power to direct the activities that most significantly impact the entities' economic performance as a result of the Company's shared or lack of control. As a result, the Company has accounted for these investments under the equity method of accounting. The Company's investment in these entities was $172.8 million and $169.2 million as of March 31, 2016 and December 31, 2015 , respectively, and is reflected in the accompanying consolidated balance sheets as a component of investments in unconsolidated affiliates. The Company has recorded its share of the earnings of these investments of $6.6 million and $2.7 million as a component of equity in earnings of the unconsolidated affiliates in the accompanying statements of earnings during the three months ended March 31, 2016 and March 31, 2015 , respectively. The Company recognized management and billing fees totaling $6.3 million and $3.4 million during the three months ended March 31, 2016 and March 31, 2015 respectively, which are included in net revenue in the accompanying consolidated statements of earnings. The Company has also recorded receivables from these entities in the amount of $8.1 million and $2.3 million as of March 31, 2016 and December 31, 2015 , respectively. These receivables are included in the other current assets in the accompanying consolidated balance sheets. Restricted Cash and Marketable Securities As of March 31, 2016 and December 31, 2015 , the Company had $26.8 million and $27.4 million , respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets the majority of which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $12.4 million and $13.9 million as of March 31, 2016 and December 31, 2015 , respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of March 31, 2016 and December 31, 2015 , the Company had $0.5 million and $2.7 million , respectively, included in restricted cash and marketable securities, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Reclassifications Certain prior year amounts in the accompanying consolidated financial statements have been reclassified to reflect the adoption of ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” as discussed further under “Recent Accounting Pronouncements.” The impact of the reclassification made to prior period balance sheet is presented below. December 31, 2015 Consolidated Balance Sheet: Previously reported Reclassification Revised Intangible assets, net $ 1,641,811 $ (47,174 ) $ 1,594,637 Long-term debt $ 2,405,130 $ (47,174 ) $ 2,357,956 Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. In March 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” clarifying how an entity should identify the unit of accounting (i.e., the specified good or service) for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements, such as service transactions, by explaining what a principal controls before the specified good or service is transferred to the customer. The guidance in ASU 2014-09 and ASU 2016-08 will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company adopted this standard effective January 1, 2016 and applied the adoption retrospectively. The adoption of the standard did not result in a change of consolidated subsidiaries nor did it result in any impact to the Company's consolidated financial position, results of operations or cash flows as of and for the three months ended March 31, 2016 or for any previous period. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporates into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2016 and accordingly, reclassified $47.2 million of deferred debt issuance costs from intangible assets, net to a reduction in long-term debt at December 31, 2015, in the accompanying balance sheets (see reclassification above). In February 2016, the FASB issued ASU No. 2016-02, “Leases” which amends existing accounting standards for lease accounting, including requiring lessees to recognize most leases on the balance sheet and making changes to lessor accounting. The standard is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The new standard requires a modified retrospective application for all leases existing at, or entered into, after the date of initial application, with an option to use certain transition relief. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” which will change how companies account for certain aspects of share-based payments to employees by requiring companies to recognize the income tax effects of awards in the income statement when the awards vest or are settled. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2016
Revenue Recognition [Abstract]
Revenue Recognition	Revenue Recognition Ambulatory Services Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor. Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the three months ended March 31, 2016 and 2015 , the Company derived approximately 26% and 25% , respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Physician Services Physician services revenues primarily consist of fee for service revenue and contract revenue and are derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors. The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period that have not been billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections. The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries). Net revenue for the physician services segment consists of the following major payors (dollars in thousands): Three Months Ended March 31, 2016 2015 Medicare $ 58,774 14 % $ 41,329 14 % Medicaid 30,825 7 18,580 6 Commercial and managed care 324,171 78 220,118 77 Self-pay 61,717 15 43,271 15 Net fee for service revenue 475,487 114 323,298 113 Contract and other revenue 35,665 9 30,989 11 Provision for uncollectibles (93,608 ) (22 ) (67,752 ) (24 ) Net revenue for physician services $ 417,544 100 % $ 286,535 100 %

Accounts Receivable

Accounts Receivable	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Accounts Receivable	Accounts Receivable The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts policy for its physician services segment quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous twelve month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates are charged or credited to the consolidated statements of operations in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third-party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows. Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statements of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statements of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statements of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for ambulatory services is included in other operating expenses and was approximately $5.8 million and $6.2 million for the three months ended March 31, 2016 and 2015 , respectively. Bad debt expense related to physician services was $93.6 million and $67.8 million for the three months ended March 31, 2016 and 2015 , respectively. At March 31, 2016 and December 31, 2015 , allowances for doubtful accounts were $188.1 million and $167.4 million , respectively. The increase in the allowance for doubtful accounts is primarily a result of having a full quarter of operations for acquisitions completed during the fourth quarter of 2015. At March 31, 2016 and December 31, 2015 , approximately 81% and 80% , respectively, of the Company’s allowance for doubtful accounts was related to fee for service patient receivables associated with the physician services segment. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of facilities, patients, payors, and by the geographic dispersion of the Company's operations.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Ambulatory Services Acquisitions During the three months ended March 31, 2015 , the Company, through a wholly-owned subsidiary, acquired a controlling interest in one surgery center. The aggregate amount paid for the center and for settlement of purchase price payable obligations during the three months ended March 31, 2015 was approximately $41.9 million , and was paid with a combination of available cash and operating cash flow. During the three months ended March 31, 2016 , the Company did not acquire any surgery centers. The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. Physician Services Acquisitions The Company completed the acquisition of one physician practice in the three months ended March 31, 2016 and three physician practices in the three months ended March 31, 2015 . The total consideration consisted of cash of $3.0 million and $84.7 million , respectively, which was funded at closing through available cash and operating cash flow. As a result of certain acquisitions completed during prior periods, the Company has agreed to pay as additional consideration amounts which are contingent on the acquired entities achieving future performance metrics. As of March 31, 2016 and December 31, 2015 , the Company had accrued $5.5 million as a component of other accrued liabilities in the accompanying consolidated balance sheets, which represents management's estimate of the fair values of the contingent consideration. As of March 31, 2016 , the Company estimates it may have to pay between $5.0 million and $6.0 million in future contingent payments for acquisitions made prior to December 31, 2015 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisitions over each respective measurement period. The acquisition completed during the three months ended March 31, 2016 did not contain provisions for contingent consideration. The Company utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the contingent consideration. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. The timing of the payments of the additional consideration varies by agreement but is expected to occur within one to three years from the respective date of acquisition. Purchase Price Allocations The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major financial class for one physician services acquisition completed in the three months ended March 31, 2016 , including post acquisition date adjustments recorded to purchase price allocations, was not significant. During 2016 , no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2015 . The total fair value of acquisitions completed by the Company include amounts allocated to goodwill, which result from the acquisitions' favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. Additionally, the Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests associated with acquisitions completed in the last 12 months. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the amortizable intangible assets recognized. The amount allocated to the deferred income tax liability is subject to change as a result of the final allocation of purchase price to amortizable intangibles. The Company expects to finalize the purchase price allocation for its most recent acquisitions as soon as practical. During the three months ended March 31, 2016 and 2015 , the Company incurred approximately $1.4 million and $1.5 million of transaction costs, respectively. During the three months ended March 31, 2016 , the net revenue and net earnings attributable to the physician practice acquisition were not considered significant. Net revenue and net earnings associated with completed acquisitions during the three months ended March 31, 2015 are as follows (in thousands): Three Months Ended March 31, 2015 Net revenue $ 14,989 Net earnings 2,613 Less: Net earnings attributable to noncontrolling interests 761 Net earnings attributable to AmSurg Corp. common shareholders $ 1,852 The unaudited consolidated pro forma results for the three months ended March 31, 2016 and 2015 , assuming all 2016 acquisitions had been consummated on January 1, 2015 , and all 2015 acquisitions had been consummated on January 1, 2014 are as follows (in thousands, except earnings per share): Three Months Ended March 31, 2016 2015 Net revenue $ 725,907 $ 673,709 Net earnings 85,536 90,887 Amounts attributable to AmSurg Corp. common shareholders: Net earnings 29,431 23,212 Net earnings per common share: Basic $ 0.55 $ 0.49 Diluted $ 0.55 $ 0.48

Investments in Unconsolidated A

Investments in Unconsolidated Affiliates	3 Months Ended
	Mar. 31, 2016
Equity Method Investments and Joint Ventures [Abstract]
Investments in Unconsolidated Affiliates	Investments in Unconsolidated Affiliates Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary. As of March 31, 2016 and December 31, 2015 , the Company recorded in the accompanying consolidated balance sheets its investments in unconsolidated affiliates of $172.8 million and $169.2 million , respectively. The Company's net earnings from these investments during the three months ended March 31, 2016 and 2015 were approximately $6.6 million and $2.7 million , respectively. During the three months ended March 31, 2015 , the Company's ambulatory services segment entered into one equity method investment. As a result of this investment, the Company contributed its controlling interest in a center and received cash of $0.6 million and a noncontrolling interest in an entity that owned one ASC prior to the transaction and, after the completion of the transaction, controls the contributed center and the center it previously owned. As a result of the transaction, the Company recorded in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates, the fair value of the Company's investment in the entity which controls the contributed center of approximately $1.3 million during the three months ended March 31, 2015 . The Company did not enter into any equity method investments during the three months ended March 31, 2016 . During the three months ended March 31, 2015 , the loss on deconsolidation, which was primarily non-cash in nature, was determined based on the difference between the fair value of the Company’s interest, which was based on estimates of the expected future earnings, in the new entity and the carrying value of both the tangible and intangible assets of the contributed center immediately prior to each transaction. During the three months ended March 31, 2015 , the Company recognized a net loss on deconsolidation in the accompanying consolidated statements of earnings of approximately $0.2 million . There was no deconsolidation activity during the three months ended March 31, 2016 .

Prepaid and Other Current Asset

Prepaid and Other Current Assets	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid and Other Current Assets	Prepaid and Other Current Assets The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, 2016 2015 Prepaid expenses $ 22,270 $ 18,900 Deferred compensation plan assets 23,018 16,623 Other 31,225 40,248 Total prepaid and other current assets $ 76,513 $ 75,771

Goodwill And Intangible Assets

Goodwill And Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets	Goodwill and Intangible Assets The changes in the carrying amount of goodwill for the three months ended March 31, 2016 are as follows (in thousands): Balance at December 31, 2015 $ 3,970,210 Goodwill acquired, including post acquisition adjustments (2,308 ) Balance at March 31, 2016 $ 3,967,902 As of March 31, 2016 , the ambulatory services segment and the physician services segment each had approximately $2.0 billion of goodwill. During the three months ended March 31, 2016 , there was not a significant change in goodwill for the ambulatory services segment. During the three months ended March 31, 2016 , goodwill decreased by $2.2 million for the physician services segment, primarily due to purchase price allocation adjustments for prior acquisitions completed during 2015 offset by the acquisition of one physician practice. For the three months ended March 31, 2016 and 2015 , respectively, approximately $1.1 million and $49.4 million of goodwill recorded was deductible for tax purposes. Intangible assets at March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Customer relationships with hospitals $ 1,381,477 $ (91,744 ) $ 1,289,733 $ 1,379,977 $ (74,490 ) $ 1,305,487 Capitalized software 76,029 (30,742 ) 45,287 71,462 (28,125 ) 43,337 Agreements, contracts and other 11,283 (2,961 ) 8,322 11,267 (2,449 ) 8,818 Total amortizable intangible assets 1,468,789 (125,447 ) 1,343,342 1,462,706 (105,064 ) 1,357,642 Non-amortizable intangible assets: Trade name 228,000 — 228,000 228,000 — 228,000 Restrictive covenant arrangements 8,995 — 8,995 8,995 — 8,995 Total non-amortizable intangible assets 236,995 — 236,995 236,995 — 236,995 Total intangible assets $ 1,705,784 $ (125,447 ) $ 1,580,337 $ 1,699,701 $ (105,064 ) $ 1,594,637 Amortization of intangible assets for the three months ended March 31, 2016 and 2015 was $20.4 million and $14.5 million , respectively. Estimated amortization of intangible assets for the remainder of 2016 and each of the following five years and thereafter is $62.1 million , $81.6 million , $80.4 million , $77.7 million , $75.4 million , $71.6 million and $894.5 million , respectively. The Company expects to recognize amortization of all intangible assets over a weighted average period of 18.0 years with no expected residual values.

Other Accrued Liabilities

Other Accrued Liabilities	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities, Current [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	Other Accrued Liabilities The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, 2016 2015 Accrued professional liabilities $ 14,319 $ 14,362 Contingent purchase price payable 5,509 5,509 Current income taxes payable 1,782 7,892 Refunds payable 45,175 48,415 Other 35,076 43,059 Total other accrued liabilities $ 101,861 $ 119,237

Accrued Professional Liabilitie

Accrued Professional Liabilities	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Accounts Professional Liabilities	Accrued Professional Liabilities The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer, which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted. At March 31, 2016 and December 31, 2015 , the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands): March 31, 2016 December 31, 2015 Estimated losses under self-insured programs $ 30,227 $ 30,748 Incurred but not reported losses 33,318 36,166 Total accrued professional liabilities 63,545 66,914 Less estimated losses payable within one year 14,319 14,362 Total $ 49,226 $ 52,552 The changes to the Company's estimated losses under self-insured programs as of March 31, 2016 were as follows (in thousands): Balance at December 31, 2015 $ 66,914 Provision related to current period reserves 4,274 Payments for prior period reserves (4,128 ) Other, net including post acquisition adjustments (3,515 ) Balance at March 31, 2016 $ 63,545

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	Long-term Debt Long-term debt at March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, December 31, 2016 2015 Revolving credit agreement $ 155,000 $ 175,000 Term loan 854,775 856,950 5.625% Senior Unsecured Notes due 2020 250,000 250,000 5.625% Senior Unsecured Notes due 2022 1,100,000 1,100,000 Other debt due through 2025 23,525 24,944 Capitalized lease arrangements due through 2026 18,262 18,613 2,401,562 2,425,507 Less current portion 20,231 20,377 Less net deferred financing costs 45,047 47,174 Long-term debt $ 2,336,284 $ 2,357,956 The fair value of fixed rate long-term debt, with a carrying value of $1,390.6 million , was $1,434.5 million at March 31, 2016 . The fair value of variable rate long-term debt approximates its carrying value of $1,011.0 million at March 31, 2016 . With the exception of the Company’s 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes (each defined below), the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company’s 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market. a. Term Loan and Credit Facility The Company has a credit facility that is comprised of an $870.0 million term loan and a $500.0 million revolving credit facility. On October 21, 2015, the Company exercised the accordion feature of its revolving credit facility and increased the Company's borrowing capacity by $200.0 million to $500.0 million . As of March 31, 2016 , the Company had available $345.0 million under the revolving credit facility. The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00% , with a LIBOR floor of 0.75% , or a combination thereof ( 3.50% on March 31, 2016 ). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually. The revolving credit facility matures on July 16, 2019 and permits the Company to borrow up to $500.0 million at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00% , or a combination thereof, and provides for a fee of 0.375% of unused commitments. The Company has the option to increase borrowings under the senior secured credit facility by an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s less than wholly-owned subsidiaries. As of March 31, 2016 , the Company was in compliance with the covenants contained in the term loan and credit facility and had not drawn upon the revolving credit facility. b. Senior Unsecured Notes 2020 Senior Unsecured Notes The Company has $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (the 2020 Senior Unsecured Notes). The 2020 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020 . The Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on November 30 of the years indicated below: Period Redemption Price 2015 104.219 % 2016 102.813 % 2017 101.406 % 2018 and thereafter 100.000 % The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2020 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory convertible preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at March 31, 2016 . 2022 Senior Unsecured Notes The Company has $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (the 2022 Senior Unsecured Notes). The 2022 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15 through the maturity date of July 15, 2022. Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on July 15 of the years indicated below: Period Redemption Price 2017 104.219 % 2018 102.813 % 2019 101.406 % 2020 and thereafter 100.000 % The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at March 31, 2016 .

Other Long-Term Liabilities

Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2016
Other Long-Term Liabilities [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]	Other Long-Term Liabilities Other long-term liabilities consist of the following (in thousands): March 31, December 31, 2016 2015 Accrued professional liabilities $ 49,226 $ 52,552 Deferred rent 21,635 18,958 Tax-effected unrecognized benefits 3,426 3,426 Other 24,720 21,247 Other long-term liabilities $ 99,007 $ 96,183

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity a. Common Stock During December 2015, the Company issued 5,835,000 shares of its common stock in a public offering, at $80.00 per share, prior to underwriting discounts, commissions, and other related offering expenses of approximately $19.1 million . Proceeds were used to repay a portion of the Company's revolving credit facility, to fund a portion of the acquisitions completed during the three months ended December 31, 2015 and for general corporate purposes. In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vests to cover payroll withholding taxes in accordance with the restricted stock agreements. During the three months ended March 31, 2016 and 2015 , the Company repurchased 77,780 shares and 67,000 shares, respectively, of common stock for approximately $5.7 million and $3.7 million , respectively. b. Preferred Stock The Company has 1,725,000 shares outstanding of its mandatory convertible preferred stock. The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100 , plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount. During each of the three months ended March 31, 2016 and 2015 , the Company's Board of Directors declared a dividend totaling $1.3125 per share in cash, or $2.3 million , for the Company’s mandatory convertible preferred stock. As of March 31, 2016 , the dividend declared in the current period was funded to the paying agent to be paid to shareholders of record as of March 15, 2016 . c. Stock Incentive Plans In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan. The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, and the AmSurg Corp. 1997 Stock Incentive Plan, as amended, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At March 31, 2016 , 1,200,000 shares were authorized for grant under the 2014 Equity and Incentive Plan and 416,463 shares were available for future equity grants. Restricted stock granted to outside directors vests on the first anniversary of the date of grant. Restricted stock granted to employees generally vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date. Under Company policy, shares held by outside directors and senior management are subject to certain holding requirements and restrictions. The Company has not issued options subsequent to 2008, and all outstanding options are fully vested. Options were granted at market value on the date of the grant and vested over four years. Outstanding options have a term of ten years from the date of grant. Other information pertaining to share-based activity during the three months ended March 31, 2016 and 2015 was as follows (in thousands): Three Months Ended March 31, 2016 2015 Share-based compensation expense $ 7,168 $ 3,709 Fair value of shares vested 16,961 11,474 Cash received from option exercises 276 1,746 Tax benefit from exercises of share based awards 3,605 3,317 As of March 31, 2016 , the Company had total unrecognized compensation cost of approximately $49.1 million related to non-vested awards, which the Company expects to recognize through 2020 and over a weighted average period of 1.3 years. For the three months ended March 31, 2016 and 2015 , there were no options that were anti-dilutive. A summary of the status of non-vested restricted shares at March 31, 2016 and changes during the three months ended March 31, 2016 is as follows: Weighted Number Average of Shares Grant Price Non-vested shares at December 31, 2015 734,101 $ 44.73 Shares granted 566,763 73.98 Shares vested (231,862 ) 36.27 Shares forfeited (5,407 ) 55.40 Non-vested shares at March 31, 2016 1,063,595 $ 62.11 In addition to the non-vested restricted shares, during the three months ended March 31, 2016 , the Company granted 73,003 performance-based restricted stock units (RSUs) to certain of its officers and physician employees. The fair value of the Company's common stock on the grant date of these RSUs was $73.98 . Subject to achieving applicable performance thresholds, the RSUs will vest ratably over a three year period from the grant date. The conversion of the RSUs to restricted stock is contingent on the Company’s achievement of a specified one -year financial performance goal for the year ended December 31, 2016 and, if achieved, would occur during the first quarter of 2017. If the financial performance goal is not achieved, the RSUs will be forfeited. The number of RSUs that will ultimately be received by the holders range from 0% to 150% of the units granted, depending on the Company’s level of achievement with respect to the financial performance goal. At March 31, 2016 , the Company believes the RSUs will vest at approximately 100% . A summary of stock option activity for the three months ended March 31, 2016 is summarized as follows: Weighted Weighted Average Average Remaining Number Exercise Contractual of Shares Price Term (in years) Outstanding at December 31, 2015 33,751 $ 22.98 1.1 Options exercised with total intrinsic value of $0.6 million (12,667 ) 21.78 Options terminated (4,200 ) 21.07 Outstanding, Vested and Exercisable at March 31, 2016 with an aggregate intrinsic value of $0.9 million 16,884 $ 24.36 0.8 The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at March 31, 2016 exercised their options at the Company’s closing stock price on March 31, 2016 . d. Earnings per Share Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive. For the three months ended March 31, 2016 and 2015 , approximately 3.1 million and 3.2 million , respectively, common share equivalents related to the mandatory convertible preferred stock were anti-dilutive and therefore are excluded from the dilutive weighted average number of shares outstanding. The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended March 31, Earnings Shares Per Share (Numerator) (Denominator) Amount 2016: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 28,599 53,665 $ 0.53 Effect of dilutive securities, options and non-vested shares — 336 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 28,599 54,001 $ 0.53 2015: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 18,774 47,572 $ 0.39 Effect of dilutive securities, options and non-vested shares — 333 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 18,774 47,905 $ 0.39

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statements of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months. The Company and its subsidiaries file U.S. federal and various state tax returns. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2012 .

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	Commitments and Contingencies Litigation From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows. Insurance Programs Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer, which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third-party insurers for its surgery centers and certain of its owned practices and employed physicians. The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value. The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. Redeemable Noncontrolling Interests Certain of the Company’s wholly-owned subsidiaries are responsible for all debts incurred but unpaid by the Company's less than wholly-owned partnerships as these subsidiaries are the general partner. As manager of the operations of these partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions. In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2016 . As a result, the noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets. Physician Services Headquarters Operating Lease On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida, which it intends to be the future headquarters of its physician services segment. The Company took possession of the space in the fourth quarter of 2015 and began tenant improvements on approximately 167,000 square feet of space, which it intends to occupy during the fourth quarter of 2016. In addition, the Company plans to begin tenant improvements on an additional 55,000 square feet of space during the third quarter of 2016, which it intends to occupy during the first quarter of 2017. Annual rent expense is expected to be approximately $2.9 million . The initial term of this lease agreement expires in February 2029.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting The Company operates in two major lines of business - the operation of ambulatory surgery centers and providing outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services, and emergency medicine. The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer. The following table presents financial information for each reportable segment (in thousands): Three Months Ended March 31, 2016 2015 Net Revenue: Ambulatory Services $ 307,134 $ 283,910 Physician Services 417,544 286,535 Total $ 724,678 $ 570,445 Adjusted EBITDA: Ambulatory Services $ 53,626 $ 47,308 Physician Services 66,474 46,447 Total $ 120,100 $ 93,755 Adjusted EBITDA: $ 120,100 $ 93,755 Earnings attributable to noncontrolling interests 53,841 47,717 Interest expense, net (30,810 ) (30,247 ) Depreciation and amortization (29,072 ) (22,818 ) Share-based compensation (7,168 ) (3,709 ) Transaction costs (1,390 ) (1,471 ) Net loss on deconsolidations — (223 ) Earnings before income taxes $ 105,501 $ 83,004 Acquisition and Capital Expenditures: Ambulatory Services $ 8,371 $ 54,096 Physician Services 10,310 87,265 Total $ 18,681 $ 141,361

Financial Information for the C

Financial Information for the Company and Its Subsidiaries	3 Months Ended
	Mar. 31, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Financial Information for the Company and Its Subsidiaries	Financial Information for the Company and Its Subsidiaries The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis. Condensed Consolidating Balance Sheet - March 31, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 9,391 $ 20,632 $ 55,860 $ — $ 85,883 Restricted cash and marketable securities — 995 13,440 — 14,435 Accounts receivable, net — 240,265 112,626 — 352,891 Supplies inventory — — 21,584 — 21,584 Prepaid and other current assets 39,908 31,317 28,637 (23,349 ) 76,513 Total current assets 49,299 293,209 232,147 (23,349 ) 551,306 Property and equipment, net 12,421 17,824 161,675 — 191,920 Investments in and receivables from unconsolidated affiliates 4,901,556 1,774,642 — (6,503,372 ) 172,826 Goodwill — 1,954,467 — 2,013,435 3,967,902 Intangible assets, net 13,142 1,565,068 2,127 — 1,580,337 Other assets 4,532 1,583 15,538 (1,998 ) 19,655 Total assets $ 4,980,950 $ 5,606,793 $ 411,487 $ (4,515,284 ) $ 6,483,946 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ 19 $ 11,512 $ — $ 20,231 Accounts payable 2,196 2,080 26,223 (4,087 ) 26,412 Accrued salaries and benefits 25,225 162,396 16,570 — 204,191 Accrued interest 17,995 — 10 — 18,005 Other accrued liabilities 8,125 67,058 45,940 (19,262 ) 101,861 Total current liabilities 62,241 231,553 100,255 (23,349 ) 370,700 Long-term debt 2,306,032 40 54,587 (24,375 ) 2,336,284 Deferred income taxes 281,498 426,952 — (1,998 ) 706,452 Other long-term liabilities 4,658 73,729 20,620 — 99,007 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 61,577 113,094 174,671 Equity: Total AmSurg Corp. equity 2,326,521 3,646,362 128,291 (3,774,653 ) 2,326,521 Noncontrolling interests – non-redeemable — — 46,157 424,154 470,311 Total equity 2,326,521 3,646,362 174,448 (3,350,499 ) 2,796,832 Total liabilities and equity $ 4,980,950 $ 5,606,793 $ 411,487 $ (4,515,284 ) $ 6,483,946 Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Restricted cash and marketable securities — — 13,506 — 13,506 Accounts receivable, net — 223,434 113,896 — 337,330 Supplies inventory — — 21,406 — 21,406 Prepaid and other current assets 28,739 39,046 16,062 (8,076 ) 75,771 Total current assets 49,176 289,987 223,586 (8,076 ) 554,673 Property and equipment, net 12,515 14,601 162,052 — 189,168 Investments in and receivables from unconsolidated affiliates 4,901,026 1,775,272 — (6,507,128 ) 169,170 Goodwill — 1,956,741 — 2,013,469 3,970,210 Intangible assets, net 12,780 1,579,537 2,320 — 1,594,637 Other assets 4,653 1,717 17,078 (1,998 ) 21,450 Total assets $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 11,677 $ — $ 20,377 Accounts payable 2,816 3,760 29,837 (3,852 ) 32,561 Accrued salaries and benefits 31,510 158,705 12,322 — 202,537 Accrued interest 30,463 — 17 — 30,480 Other accrued liabilities 13,962 76,590 32,909 (4,224 ) 119,237 Total current liabilities 87,451 239,055 86,762 (8,076 ) 405,192 Long-term debt 2,326,103 — 55,249 (23,396 ) 2,357,956 Deferred income taxes 268,573 432,923 — (1,998 ) 699,498 Other long-term liabilities 4,560 71,509 20,114 — 96,183 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 63,060 112,672 175,732 Equity: Total AmSurg Corp. equity 2,293,463 3,646,211 132,267 (3,778,478 ) 2,293,463 Noncontrolling interests – non-redeemable — — 47,584 423,700 471,284 Total equity 2,293,463 3,646,211 179,851 (3,354,778 ) 2,764,747 Total liabilities and equity $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308 Condensed Consolidating Statement of Operations - For the Three Months Ended March 31, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 8,544 $ 415,830 $ 310,612 $ (10,308 ) $ 724,678 Operating expenses: Salaries and benefits 24,095 309,580 76,297 (133 ) 409,839 Supply cost — 1,007 45,969 (13 ) 46,963 Other operating expenses 7,618 43,339 66,887 (10,162 ) 107,682 Transaction costs 177 1,213 — — 1,390 Depreciation and amortization 1,072 20,336 7,664 — 29,072 Total operating expenses 32,962 375,475 196,817 (10,308 ) 594,946 Equity in earnings of unconsolidated affiliates 69,042 65,436 — (127,899 ) 6,579 Operating income 44,624 105,791 113,795 (127,899 ) 136,311 Interest expense (income), net (2,819 ) 32,976 653 — 30,810 Earnings before income taxes 47,443 72,815 113,142 (127,899 ) 105,501 Income tax expense 16,580 3,774 443 — 20,797 Net earnings 30,863 69,041 112,699 (127,899 ) 84,704 Less net earnings attributable to noncontrolling interests — — 53,841 — 53,841 Net earnings attributable to AmSurg Corp. shareholders 30,863 69,041 58,858 (127,899 ) 30,863 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 28,599 $ 69,041 $ 58,858 $ (127,899 ) $ 28,599 Condensed Consolidating Statement of Operations - For the Three Months Ended March 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 7,091 $ 285,579 $ 286,629 $ (8,854 ) $ 570,445 Operating expenses: Salaries and benefits 17,643 211,601 73,063 (128 ) 302,179 Supply cost — 396 42,188 — 42,584 Other operating expenses 6,634 29,611 63,051 (8,726 ) 90,570 Transaction costs 268 1,203 — — 1,471 Depreciation and amortization 834 14,307 7,677 — 22,818 Total operating expenses 25,379 257,118 185,979 (8,854 ) 459,622 Net loss on deconsolidations (188 ) (188 ) (35 ) 188 (223 ) Equity in earnings of unconsolidated affiliates 60,387 54,583 — (112,319 ) 2,651 Operating income 41,911 82,856 100,615 (112,131 ) 113,251 Interest expense, net 11,886 17,754 607 — 30,247 Earnings before income taxes 30,025 65,102 100,008 (112,131 ) 83,004 Income tax expense 8,987 4,903 359 — 14,249 Net earnings 21,038 60,199 99,649 (112,131 ) 68,755 Less net earnings attributable to noncontrolling interests — — 47,717 — 47,717 Net earnings attributable to AmSurg Corp. shareholders 21,038 60,199 51,932 (112,131 ) 21,038 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 18,774 $ 60,199 $ 51,932 $ (112,131 ) $ 18,774 Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 18,122 $ 72,860 $ 122,490 $ (131,699 ) $ 81,773 Cash flows from investing activities: Acquisitions and related expenses — (2,990 ) — — (2,990 ) Acquisition of property and equipment (1,509 ) (7,320 ) (6,862 ) — (15,691 ) Maturities of marketable securities — — 2,240 — 2,240 Other — (878 ) (631 ) — (1,509 ) Net cash flows used in investing activities (1,509 ) (11,188 ) (5,253 ) — (17,950 ) Cash flows from financing activities: Proceeds from long-term borrowings 15,000 — 1,197 — 16,197 Repayment on long-term borrowings (37,175 ) — (3,157 ) — (40,332 ) Distributions to owners, including noncontrolling interests — (68,547 ) (119,953 ) 131,699 (56,801 ) Changes in intercompany balances with affiliates, net (979 ) — 979 — — Other, net (4,505 ) — 841 — (3,664 ) Net cash flows used in financing activities (27,659 ) (68,547 ) (120,093 ) 131,699 (84,600 ) Net decrease in cash and cash equivalents (11,046 ) (6,875 ) (2,856 ) — (20,777 ) Cash and cash equivalents, beginning of period 20,437 27,507 58,716 — 106,660 Cash and cash equivalents, end of period $ 9,391 $ 20,632 $ 55,860 $ — $ 85,883 Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by (used in) operating activities $ (33,779 ) $ 91,981 $ 102,821 $ (62,196 ) $ 98,827 Cash flows from investing activities: Acquisitions and related expenses (62,056 ) (127,047 ) — 62,525 (126,578 ) Acquisition of property and equipment (2,678 ) (2,538 ) (9,567 ) — (14,783 ) Other — (1,322 ) 1,102 — (220 ) Net cash flows used in investing activities (64,734 ) (130,907 ) (8,465 ) 62,525 (141,581 ) Cash flows from financing activities: Proceeds from long-term borrowings — — 2,227 — 2,227 Repayment on long-term borrowings (2,175 ) — (3,038 ) — (5,213 ) Distributions to owners, including noncontrolling interests — (10,241 ) (99,157 ) 62,196 (47,202 ) Capital contributions — 62,056 — (62,056 ) — Changes in intercompany balances with affiliates, net (2,573 ) — 2,573 — — Other, net (972 ) 2,321 139 (469 ) 1,019 Net cash flows provided by (used in) financing activities (5,720 ) 54,136 (97,256 ) (329 ) (49,169 ) Net increase (decrease) in cash and cash equivalents (104,233 ) 15,210 (2,900 ) — (91,923 ) Cash and cash equivalents, beginning of period 134,351 23,471 50,257 — 208,079 Cash and cash equivalents, end of period $ 30,118 $ 38,681 $ 47,357 $ — $ 116,156

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all normal recurring adjustments, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in AmSurg Corp.'s (Company) Annual Report on Form 10-K for the fiscal year ended December 31, 2015 . Ambulatory Services The Company, through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ambulatory surgery centers (ASCs, surgery centers or centers). All LLCs and LPs are referred to herein as “partnerships” and “partners”, respectively. The Company has variable interests in the partnerships through its equity ownership interests. Each partnership is considered a variable interest entity (VIE) due to its structure as a limited partnership or functional equivalent under Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2015-02 “Consolidations (Topic 810) - Amendments to the Consolidation Analysis,” which was adopted effective January 1, 2016. For those partnerships in which the Company’s ownership interest is 51% or greater, the Company is considered the primary beneficiary. The Company is the primary beneficiary due to 1) ownership interest, operating agreements allowing the Company to govern the day-to-day activities, and the Company’s position as the managing member or general partner and 2) the Company's obligation to absorb losses or the right to receive returns proportionate to its equity interest in the partnerships. For the 23 partnerships in which the Company’s ownership interest is less than 51%, the Company is not deemed the primary beneficiary and therefore those partnerships are not consolidated with the exception of 2 partnerships which are consolidated because the Company holds substantive participation rights and has the obligation to absorb losses or right to receive returns proportionate to its equity interest in the partnerships. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated partnerships. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net earnings attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis. Physician Services The Company, through its wholly-owned subsidiary Sheridan Healthcare, is also a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. The Company focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, the Company is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. The Company also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which the Company has management arrangements. The Company's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned subsidiaries. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “ Consolidations. ”
Restricted Cash	Restricted Cash and Marketable Securities As of March 31, 2016 and December 31, 2015 , the Company had $26.8 million and $27.4 million , respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets the majority of which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $12.4 million and $13.9 million as of March 31, 2016 and December 31, 2015 , respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of March 31, 2016 and December 31, 2015 , the Company had $0.5 million and $2.7 million , respectively, included in restricted cash and marketable securities, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.
Reclassifications	Reclassifications Certain prior year amounts in the accompanying consolidated financial statements have been reclassified to reflect the adoption of ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” as discussed further under “Recent Accounting Pronouncements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. In March 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” clarifying how an entity should identify the unit of accounting (i.e., the specified good or service) for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements, such as service transactions, by explaining what a principal controls before the specified good or service is transferred to the customer. The guidance in ASU 2014-09 and ASU 2016-08 will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company adopted this standard effective January 1, 2016 and applied the adoption retrospectively. The adoption of the standard did not result in a change of consolidated subsidiaries nor did it result in any impact to the Company's consolidated financial position, results of operations or cash flows as of and for the three months ended March 31, 2016 or for any previous period. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporates into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2016 and accordingly, reclassified $47.2 million of deferred debt issuance costs from intangible assets, net to a reduction in long-term debt at December 31, 2015, in the accompanying balance sheets (see reclassification above). In February 2016, the FASB issued ASU No. 2016-02, “Leases” which amends existing accounting standards for lease accounting, including requiring lessees to recognize most leases on the balance sheet and making changes to lessor accounting. The standard is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The new standard requires a modified retrospective application for all leases existing at, or entered into, after the date of initial application, with an option to use certain transition relief. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” which will change how companies account for certain aspects of share-based payments to employees by requiring companies to recognize the income tax effects of awards in the income statement when the awards vest or are settled. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has not yet determined the impact this ASU will have on the Company's consolidated financial position, results of operations or cash flows.
Revenue Recognition	Ambulatory Services Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor. Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the three months ended March 31, 2016 and 2015 , the Company derived approximately 26% and 25% , respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Physician Services Physician services revenues primarily consist of fee for service revenue and contract revenue and are derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors. The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period that have not been billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections. The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).
Accounts Receivable	The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts policy for its physician services segment quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous twelve month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates are charged or credited to the consolidated statements of operations in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third-party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows. Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statements of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statements of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statements of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent.
Acquisitions	The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.
Investments in Unconsolidated Affiliates	Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
Earnings per Share	Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.
Income Taxes	The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statements of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.
Insurance Programs	Insurance Programs Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer, which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third-party insurers for its surgery centers and certain of its owned practices and employed physicians. The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value.
Segments	The Company operates in two major lines of business - the operation of ambulatory surgery centers and providing outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services, and emergency medicine. The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncement Impact	The impact of the reclassification made to prior period balance sheet is presented below. December 31, 2015 Consolidated Balance Sheet: Previously reported Reclassification Revised Intangible assets, net $ 1,641,811 $ (47,174 ) $ 1,594,637 Long-term debt $ 2,405,130 $ (47,174 ) $ 2,357,956

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2016
Revenue Recognition [Abstract]
Schedule of Revenue and Fees by Segment and Major Payors	Net revenue for the physician services segment consists of the following major payors (dollars in thousands): Three Months Ended March 31, 2016 2015 Medicare $ 58,774 14 % $ 41,329 14 % Medicaid 30,825 7 18,580 6 Commercial and managed care 324,171 78 220,118 77 Self-pay 61,717 15 43,271 15 Net fee for service revenue 475,487 114 323,298 113 Contract and other revenue 35,665 9 30,989 11 Provision for uncollectibles (93,608 ) (22 ) (67,752 ) (24 ) Net revenue for physician services $ 417,544 100 % $ 286,535 100 %

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Revenues And Net Earnings Associated With Acquisitions	Net revenue and net earnings associated with completed acquisitions during the three months ended March 31, 2015 are as follows (in thousands): Three Months Ended March 31, 2015 Net revenue $ 14,989 Net earnings 2,613 Less: Net earnings attributable to noncontrolling interests 761 Net earnings attributable to AmSurg Corp. common shareholders $ 1,852
Consolidated Pro Forma Results Of Acquisition	The unaudited consolidated pro forma results for the three months ended March 31, 2016 and 2015 , assuming all 2016 acquisitions had been consummated on January 1, 2015 , and all 2015 acquisitions had been consummated on January 1, 2014 are as follows (in thousands, except earnings per share): Three Months Ended March 31, 2016 2015 Net revenue $ 725,907 $ 673,709 Net earnings 85,536 90,887 Amounts attributable to AmSurg Corp. common shareholders: Net earnings 29,431 23,212 Net earnings per common share: Basic $ 0.55 $ 0.49 Diluted $ 0.55 $ 0.48

Prepaid and Other Current Ass27

Prepaid and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid and Other Current Assets	The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, 2016 2015 Prepaid expenses $ 22,270 $ 18,900 Deferred compensation plan assets 23,018 16,623 Other 31,225 40,248 Total prepaid and other current assets $ 76,513 $ 75,771

Goodwill And Intangible Assets

Goodwill And Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Changes In Carrying Amount Of Goodwill	The changes in the carrying amount of goodwill for the three months ended March 31, 2016 are as follows (in thousands): Balance at December 31, 2015 $ 3,970,210 Goodwill acquired, including post acquisition adjustments (2,308 ) Balance at March 31, 2016 $ 3,967,902
Schedule of Finite-Lived Intangible Assets	Intangible assets at March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Customer relationships with hospitals $ 1,381,477 $ (91,744 ) $ 1,289,733 $ 1,379,977 $ (74,490 ) $ 1,305,487 Capitalized software 76,029 (30,742 ) 45,287 71,462 (28,125 ) 43,337 Agreements, contracts and other 11,283 (2,961 ) 8,322 11,267 (2,449 ) 8,818 Total amortizable intangible assets 1,468,789 (125,447 ) 1,343,342 1,462,706 (105,064 ) 1,357,642 Non-amortizable intangible assets: Trade name 228,000 — 228,000 228,000 — 228,000 Restrictive covenant arrangements 8,995 — 8,995 8,995 — 8,995 Total non-amortizable intangible assets 236,995 — 236,995 236,995 — 236,995 Total intangible assets $ 1,705,784 $ (125,447 ) $ 1,580,337 $ 1,699,701 $ (105,064 ) $ 1,594,637

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities, Current [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, 2016 2015 Accrued professional liabilities $ 14,319 $ 14,362 Contingent purchase price payable 5,509 5,509 Current income taxes payable 1,782 7,892 Refunds payable 45,175 48,415 Other 35,076 43,059 Total other accrued liabilities $ 101,861 $ 119,237

Accrued Professional Liabilit30

Accrued Professional Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Professional Liabilities	At March 31, 2016 and December 31, 2015 , the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands): March 31, 2016 December 31, 2015 Estimated losses under self-insured programs $ 30,227 $ 30,748 Incurred but not reported losses 33,318 36,166 Total accrued professional liabilities 63,545 66,914 Less estimated losses payable within one year 14,319 14,362 Total $ 49,226 $ 52,552
Schedule of Self Insurance Reserve Roll Forward	The changes to the Company's estimated losses under self-insured programs as of March 31, 2016 were as follows (in thousands): Balance at December 31, 2015 $ 66,914 Provision related to current period reserves 4,274 Payments for prior period reserves (4,128 ) Other, net including post acquisition adjustments (3,515 ) Balance at March 31, 2016 $ 63,545

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Components Of Long-Term Debt	Long-term debt at March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, December 31, 2016 2015 Revolving credit agreement $ 155,000 $ 175,000 Term loan 854,775 856,950 5.625% Senior Unsecured Notes due 2020 250,000 250,000 5.625% Senior Unsecured Notes due 2022 1,100,000 1,100,000 Other debt due through 2025 23,525 24,944 Capitalized lease arrangements due through 2026 18,262 18,613 2,401,562 2,425,507 Less current portion 20,231 20,377 Less net deferred financing costs 45,047 47,174 Long-term debt $ 2,336,284 $ 2,357,956
Redemption Price Percentage	The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on July 15 of the years indicated below: Period Redemption Price 2017 104.219 % 2018 102.813 % 2019 101.406 % 2020 and thereafter 100.000 % The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve month period beginning on November 30 of the years indicated below: Period Redemption Price 2015 104.219 % 2016 102.813 % 2017 101.406 % 2018 and thereafter 100.000 %

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Other Long-Term Liabilities [Abstract]
Other Noncurrent Liabilities	Other long-term liabilities consist of the following (in thousands): March 31, December 31, 2016 2015 Accrued professional liabilities $ 49,226 $ 52,552 Deferred rent 21,635 18,958 Tax-effected unrecognized benefits 3,426 3,426 Other 24,720 21,247 Other long-term liabilities $ 99,007 $ 96,183

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Share-Based Activity	Other information pertaining to share-based activity during the three months ended March 31, 2016 and 2015 was as follows (in thousands): Three Months Ended March 31, 2016 2015 Share-based compensation expense $ 7,168 $ 3,709 Fair value of shares vested 16,961 11,474 Cash received from option exercises 276 1,746 Tax benefit from exercises of share based awards 3,605 3,317
Schedule Of Changes In Non-Vested Restricted Shares	A summary of the status of non-vested restricted shares at March 31, 2016 and changes during the three months ended March 31, 2016 is as follows: Weighted Number Average of Shares Grant Price Non-vested shares at December 31, 2015 734,101 $ 44.73 Shares granted 566,763 73.98 Shares vested (231,862 ) 36.27 Shares forfeited (5,407 ) 55.40 Non-vested shares at March 31, 2016 1,063,595 $ 62.11
Schedule Of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2016 is summarized as follows: Weighted Weighted Average Average Remaining Number Exercise Contractual of Shares Price Term (in years) Outstanding at December 31, 2015 33,751 $ 22.98 1.1 Options exercised with total intrinsic value of $0.6 million (12,667 ) 21.78 Options terminated (4,200 ) 21.07 Outstanding, Vested and Exercisable at March 31, 2016 with an aggregate intrinsic value of $0.9 million 16,884 $ 24.36 0.8
Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share	The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended March 31, Earnings Shares Per Share (Numerator) (Denominator) Amount 2016: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 28,599 53,665 $ 0.53 Effect of dilutive securities, options and non-vested shares — 336 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 28,599 54,001 $ 0.53 2015: Net earnings attributable to AmSurg Corp. common shareholders (basic) $ 18,774 47,572 $ 0.39 Effect of dilutive securities, options and non-vested shares — 333 Net earnings attributable to AmSurg Corp. common shareholders (diluted) $ 18,774 47,905 $ 0.39

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents financial information for each reportable segment (in thousands): Three Months Ended March 31, 2016 2015 Net Revenue: Ambulatory Services $ 307,134 $ 283,910 Physician Services 417,544 286,535 Total $ 724,678 $ 570,445 Adjusted EBITDA: Ambulatory Services $ 53,626 $ 47,308 Physician Services 66,474 46,447 Total $ 120,100 $ 93,755 Adjusted EBITDA: $ 120,100 $ 93,755 Earnings attributable to noncontrolling interests 53,841 47,717 Interest expense, net (30,810 ) (30,247 ) Depreciation and amortization (29,072 ) (22,818 ) Share-based compensation (7,168 ) (3,709 ) Transaction costs (1,390 ) (1,471 ) Net loss on deconsolidations — (223 ) Earnings before income taxes $ 105,501 $ 83,004 Acquisition and Capital Expenditures: Ambulatory Services $ 8,371 $ 54,096 Physician Services 10,310 87,265 Total $ 18,681 $ 141,361

Financial Information for the35

Financial Information for the Company and Its Subsidiaries (Tables)	3 Months Ended
	Mar. 31, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet - March 31, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 9,391 $ 20,632 $ 55,860 $ — $ 85,883 Restricted cash and marketable securities — 995 13,440 — 14,435 Accounts receivable, net — 240,265 112,626 — 352,891 Supplies inventory — — 21,584 — 21,584 Prepaid and other current assets 39,908 31,317 28,637 (23,349 ) 76,513 Total current assets 49,299 293,209 232,147 (23,349 ) 551,306 Property and equipment, net 12,421 17,824 161,675 — 191,920 Investments in and receivables from unconsolidated affiliates 4,901,556 1,774,642 — (6,503,372 ) 172,826 Goodwill — 1,954,467 — 2,013,435 3,967,902 Intangible assets, net 13,142 1,565,068 2,127 — 1,580,337 Other assets 4,532 1,583 15,538 (1,998 ) 19,655 Total assets $ 4,980,950 $ 5,606,793 $ 411,487 $ (4,515,284 ) $ 6,483,946 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ 19 $ 11,512 $ — $ 20,231 Accounts payable 2,196 2,080 26,223 (4,087 ) 26,412 Accrued salaries and benefits 25,225 162,396 16,570 — 204,191 Accrued interest 17,995 — 10 — 18,005 Other accrued liabilities 8,125 67,058 45,940 (19,262 ) 101,861 Total current liabilities 62,241 231,553 100,255 (23,349 ) 370,700 Long-term debt 2,306,032 40 54,587 (24,375 ) 2,336,284 Deferred income taxes 281,498 426,952 — (1,998 ) 706,452 Other long-term liabilities 4,658 73,729 20,620 — 99,007 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 61,577 113,094 174,671 Equity: Total AmSurg Corp. equity 2,326,521 3,646,362 128,291 (3,774,653 ) 2,326,521 Noncontrolling interests – non-redeemable — — 46,157 424,154 470,311 Total equity 2,326,521 3,646,362 174,448 (3,350,499 ) 2,796,832 Total liabilities and equity $ 4,980,950 $ 5,606,793 $ 411,487 $ (4,515,284 ) $ 6,483,946 Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Restricted cash and marketable securities — — 13,506 — 13,506 Accounts receivable, net — 223,434 113,896 — 337,330 Supplies inventory — — 21,406 — 21,406 Prepaid and other current assets 28,739 39,046 16,062 (8,076 ) 75,771 Total current assets 49,176 289,987 223,586 (8,076 ) 554,673 Property and equipment, net 12,515 14,601 162,052 — 189,168 Investments in and receivables from unconsolidated affiliates 4,901,026 1,775,272 — (6,507,128 ) 169,170 Goodwill — 1,956,741 — 2,013,469 3,970,210 Intangible assets, net 12,780 1,579,537 2,320 — 1,594,637 Other assets 4,653 1,717 17,078 (1,998 ) 21,450 Total assets $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 11,677 $ — $ 20,377 Accounts payable 2,816 3,760 29,837 (3,852 ) 32,561 Accrued salaries and benefits 31,510 158,705 12,322 — 202,537 Accrued interest 30,463 — 17 — 30,480 Other accrued liabilities 13,962 76,590 32,909 (4,224 ) 119,237 Total current liabilities 87,451 239,055 86,762 (8,076 ) 405,192 Long-term debt 2,326,103 — 55,249 (23,396 ) 2,357,956 Deferred income taxes 268,573 432,923 — (1,998 ) 699,498 Other long-term liabilities 4,560 71,509 20,114 — 96,183 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 63,060 112,672 175,732 Equity: Total AmSurg Corp. equity 2,293,463 3,646,211 132,267 (3,778,478 ) 2,293,463 Noncontrolling interests – non-redeemable — — 47,584 423,700 471,284 Total equity 2,293,463 3,646,211 179,851 (3,354,778 ) 2,764,747 Total liabilities and equity $ 4,980,150 $ 5,617,855 $ 405,036 $ (4,503,733 ) $ 6,499,308
Condensed Consolidating Statement of Operations	Condensed Consolidating Statement of Operations - For the Three Months Ended March 31, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 8,544 $ 415,830 $ 310,612 $ (10,308 ) $ 724,678 Operating expenses: Salaries and benefits 24,095 309,580 76,297 (133 ) 409,839 Supply cost — 1,007 45,969 (13 ) 46,963 Other operating expenses 7,618 43,339 66,887 (10,162 ) 107,682 Transaction costs 177 1,213 — — 1,390 Depreciation and amortization 1,072 20,336 7,664 — 29,072 Total operating expenses 32,962 375,475 196,817 (10,308 ) 594,946 Equity in earnings of unconsolidated affiliates 69,042 65,436 — (127,899 ) 6,579 Operating income 44,624 105,791 113,795 (127,899 ) 136,311 Interest expense (income), net (2,819 ) 32,976 653 — 30,810 Earnings before income taxes 47,443 72,815 113,142 (127,899 ) 105,501 Income tax expense 16,580 3,774 443 — 20,797 Net earnings 30,863 69,041 112,699 (127,899 ) 84,704 Less net earnings attributable to noncontrolling interests — — 53,841 — 53,841 Net earnings attributable to AmSurg Corp. shareholders 30,863 69,041 58,858 (127,899 ) 30,863 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 28,599 $ 69,041 $ 58,858 $ (127,899 ) $ 28,599 Condensed Consolidating Statement of Operations - For the Three Months Ended March 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 7,091 $ 285,579 $ 286,629 $ (8,854 ) $ 570,445 Operating expenses: Salaries and benefits 17,643 211,601 73,063 (128 ) 302,179 Supply cost — 396 42,188 — 42,584 Other operating expenses 6,634 29,611 63,051 (8,726 ) 90,570 Transaction costs 268 1,203 — — 1,471 Depreciation and amortization 834 14,307 7,677 — 22,818 Total operating expenses 25,379 257,118 185,979 (8,854 ) 459,622 Net loss on deconsolidations (188 ) (188 ) (35 ) 188 (223 ) Equity in earnings of unconsolidated affiliates 60,387 54,583 — (112,319 ) 2,651 Operating income 41,911 82,856 100,615 (112,131 ) 113,251 Interest expense, net 11,886 17,754 607 — 30,247 Earnings before income taxes 30,025 65,102 100,008 (112,131 ) 83,004 Income tax expense 8,987 4,903 359 — 14,249 Net earnings 21,038 60,199 99,649 (112,131 ) 68,755 Less net earnings attributable to noncontrolling interests — — 47,717 — 47,717 Net earnings attributable to AmSurg Corp. shareholders 21,038 60,199 51,932 (112,131 ) 21,038 Preferred stock dividends (2,264 ) — — — (2,264 ) Net earnings attributable to AmSurg Corp. common shareholders $ 18,774 $ 60,199 $ 51,932 $ (112,131 ) $ 18,774
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2016 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 18,122 $ 72,860 $ 122,490 $ (131,699 ) $ 81,773 Cash flows from investing activities: Acquisitions and related expenses — (2,990 ) — — (2,990 ) Acquisition of property and equipment (1,509 ) (7,320 ) (6,862 ) — (15,691 ) Maturities of marketable securities — — 2,240 — 2,240 Other — (878 ) (631 ) — (1,509 ) Net cash flows used in investing activities (1,509 ) (11,188 ) (5,253 ) — (17,950 ) Cash flows from financing activities: Proceeds from long-term borrowings 15,000 — 1,197 — 16,197 Repayment on long-term borrowings (37,175 ) — (3,157 ) — (40,332 ) Distributions to owners, including noncontrolling interests — (68,547 ) (119,953 ) 131,699 (56,801 ) Changes in intercompany balances with affiliates, net (979 ) — 979 — — Other, net (4,505 ) — 841 — (3,664 ) Net cash flows used in financing activities (27,659 ) (68,547 ) (120,093 ) 131,699 (84,600 ) Net decrease in cash and cash equivalents (11,046 ) (6,875 ) (2,856 ) — (20,777 ) Cash and cash equivalents, beginning of period 20,437 27,507 58,716 — 106,660 Cash and cash equivalents, end of period $ 9,391 $ 20,632 $ 55,860 $ — $ 85,883 Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by (used in) operating activities $ (33,779 ) $ 91,981 $ 102,821 $ (62,196 ) $ 98,827 Cash flows from investing activities: Acquisitions and related expenses (62,056 ) (127,047 ) — 62,525 (126,578 ) Acquisition of property and equipment (2,678 ) (2,538 ) (9,567 ) — (14,783 ) Other — (1,322 ) 1,102 — (220 ) Net cash flows used in investing activities (64,734 ) (130,907 ) (8,465 ) 62,525 (141,581 ) Cash flows from financing activities: Proceeds from long-term borrowings — — 2,227 — 2,227 Repayment on long-term borrowings (2,175 ) — (3,038 ) — (5,213 ) Distributions to owners, including noncontrolling interests — (10,241 ) (99,157 ) 62,196 (47,202 ) Capital contributions — 62,056 — (62,056 ) — Changes in intercompany balances with affiliates, net (2,573 ) — 2,573 — — Other, net (972 ) 2,321 139 (469 ) 1,019 Net cash flows provided by (used in) financing activities (5,720 ) 54,136 (97,256 ) (329 ) (49,169 ) Net increase (decrease) in cash and cash equivalents (104,233 ) 15,210 (2,900 ) — (91,923 ) Cash and cash equivalents, beginning of period 134,351 23,471 50,257 — 208,079 Cash and cash equivalents, end of period $ 30,118 $ 38,681 $ 47,357 $ — $ 116,156

Basis of Presentation (Details)

Basis of Presentation (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)center	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)
Variable Interest Entity [Line Items]
Number of ownership interests of less than 51% | center	23
Investments in unconsolidated affiliates	$ 172,826		$ 169,170
Income (Loss) from Equity Method Investments	6,579	$ 2,651
Net revenue	724,678	570,445
Prepaid and other current assets	76,513		75,771
Restricted Cash and Marketable Securities
Restricted cash and marketable securities, total	26,800		27,400
Restricted cash and investments, noncurrent	12,400		13,900
Restricted marketable securities	500		2,700
Variable Interest Entity, Primary Beneficiary, Aggregated Disclosure [Member]
Variable Interest Entity [Line Items]
Assets of VIEs	735,300		740,100
Liabilities of VIEs	299,300		299,000
Restricted use assets of VIEs	174,400		176,800
Debt of VIEs guaranteed by AmSurg	$ 17,400		21,700
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Variable Interest Entity [Line Items]
Percent of voting rights in unconsolidated affiliates	50.00%
Investments in unconsolidated affiliates	$ 172,800		169,200
Income (Loss) from Equity Method Investments	6,600	2,700
Net revenue	6,300	$ 3,400
Prepaid and other current assets	$ 8,100		$ 2,300
Consolidated [Member]
Variable Interest Entity [Line Items]
Number of ownership interests of less than 51% | center	2

Basis of Presentation - Reclass

Basis of Presentation - Reclassifications (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible assets, net	$ 1,580,337	$ 1,594,637
Long-term debt	2,336,284	2,357,956
Deferred debt issuance costs	$ (45,047)	(47,174)
Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible assets, net		(47,174)
Long-term debt		(47,174)
Accounting Standards Update 2015-03 [Member] | Intangible Assets, Net [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred debt issuance costs		(47,200)
Accounting Standards Update 2015-03 [Member] | Long-term Debt [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred debt issuance costs		47,200
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible assets, net		1,641,811
Long-term debt		$ 2,405,130

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue, Major Customer [Line Items]
Provision for uncollectibles	$ (99,440)	$ (73,999)
Net revenue	$ 724,678	$ 570,445
Ambulatory Services [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues from governmental healthcare programs	26.00%	25.00%
Net revenue	$ 307,134	$ 283,910
Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	475,487	323,298
Contract and other revenue	35,665	30,989
Provision for uncollectibles	(93,608)	(67,752)
Net revenue	417,544	286,535
Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	58,774	41,329
Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	30,825	18,580
Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	324,171	220,118
Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	$ 61,717	$ 43,271
Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	100.00%	100.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	114.00%	113.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	14.00%	14.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	7.00%	6.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	78.00%	77.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	15.00%	15.00%
Contract and Other Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	9.00%	11.00%
Provision for Uncollectibles [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	22.00%	24.00%

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 99,440	$ 73,999
Allowances for accounts receivable	$ 188,086		$ 167,411
Product Concentration Risk [Member] | Allowance for Doubtful Accounts [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts related to fee for service patient visits	81.00%		80.00%
Ambulatory Services [Member] | Other Operating Expenses [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 5,800	6,200
Physician Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 93,608	$ 67,752

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)physician_practicecenter	Mar. 31, 2015USD ($)physician_practicecenter	Dec. 31, 2015USD ($)
Business Acquisition [Line Items]
Acquisitions and related expenses, net	$ 2,990	$ 126,578
Transaction costs	1,390	1,471
Ambulatory Services [Member]
Business Acquisition [Line Items]
Acquisitions and related expenses, net	$ 0	$ 41,900
Ambulatory Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center	0	1
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Number of business acquisitions | physician_practice	1	3
Cash paid to acquire business	$ 3,000	$ 84,700
Accrued liability, contingent consideration	5,500		$ 5,500
Contingent consideration arrangements, low	5,000
Contingent consideration arrangements, high	$ 6,000

Acquisitions (Revs and Earnings

Acquisitions (Revs and Earnings) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Acquisition [Line Items]
Net revenue	$ 724,678	$ 570,445
Net earnings	84,704	68,755
Less: Net earnings attributable to noncontrolling interests	53,841	47,717
Net earnings attributable to AmSurg Corp. shareholders	$ 30,863	21,038
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Net revenue		14,989
Net earnings		2,613
Less: Net earnings attributable to noncontrolling interests		761
Net earnings attributable to AmSurg Corp. shareholders		$ 1,852

Acquisitions (Consolidated Pro

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Combinations [Abstract]
Net revenue	$ 725,907	$ 673,709
Net earnings	85,536	90,887
Net earnings attributable to AmSurg Corp. common shareholders	$ 29,431	$ 23,212
Net earnings per common share, Basic (usd per share)	$ 0.55	$ 0.49
Net earnings per common share, Diluted (usd per share)	$ 0.55	$ 0.48

Investments in Unconsolidated43

Investments in Unconsolidated Affiliates (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)equity_method_investment	Mar. 31, 2015USD ($)equity_method_investment	Dec. 31, 2015USD ($)
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 172,826		$ 169,170
Equity in earnings of unconsolidated affiliates	6,579	$ 2,651
Net loss on deconsolidation	$ 0	$ (223)
Joint Venture [Member] | Ambulatory Services [Member] | Noncontrolling Interest In Centers [Member]
Schedule of Equity Method Investments [Line Items]
Number of separate equity method investments | equity_method_investment	0	1
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 172,800		$ 169,200
Equity in earnings of unconsolidated affiliates	$ 6,600	$ 2,700
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates		1,300
Deconsolidation [Member] | Ambulatory Services [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from Divestiture of Interest in Consolidated Subsidiaries		$ 600

Prepaid and Other Current Ass44

Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 22,270	$ 18,900
Deferred compensation plan assets	23,018	16,623
Other	31,225	40,248
Total prepaid and other current assets	$ 76,513	$ 75,771

Goodwill And Intangible Asset45

Goodwill And Intangible Assets (Narrative) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)physician_practice	Mar. 31, 2015USD ($)physician_practice	Dec. 31, 2015USD ($)
Segment Reporting Information [Line Items]
Goodwill	$ 3,967,902		$ 3,970,210
Decrease in goodwill	(2,308)
Goodwill deductible for tax purposes	1,100	$ 49,400
Amortization of Intangible Assets	20,400	$ 14,500
Estimated amortization of intangible assets, remainder of 2016	62,100
Estimated amortization of intangible assets, 2017	81,600
Estimated amortization of intangible assets, 2018	80,400
Estimated amortization of intangible assets, 2019	77,700
Estimated amortization of intangible assets, 2020	75,400
Estimated amortization of intangible assets, 2021	71,600
Estimated amortization of intangible assets, 2022 and thereafter	$ 894,500
Weighted average amortization period	18 years
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Goodwill	$ 2,000,000
Physician Services [Member]
Segment Reporting Information [Line Items]
Goodwill	2,000,000
Decrease in goodwill	$ (2,200)
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | physician_practice	1	3

Goodwill And Intangible Asset46

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill [Roll Forward]
Balance, beginning of period	$ 3,970,210
Goodwill acquired, including post acquisition adjustments	(2,308)
Balance, end of period	$ 3,967,902

Goodwill And Intangible Asset47

Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$ 236,995	$ 236,995
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,468,789	1,462,706
Accumulated Amortization	(125,447)	(105,064)
Net	1,343,342	1,357,642
Total intangible assets, gross carrying amount	1,705,784	1,699,701
Accumulated Amortization	(125,447)	(105,064)
Total intangible assets, net	1,580,337	1,594,637
Trade name [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	228,000	228,000
Restrictive covenant arrangements [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	8,995	8,995
Customer relationships with hospitals [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,381,477	1,379,977
Accumulated Amortization	(91,744)	(74,490)
Net	1,289,733	1,305,487
Accumulated Amortization	(91,744)	(74,490)
Capitalized software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	76,029	71,462
Accumulated Amortization	(30,742)	(28,125)
Net	45,287	43,337
Accumulated Amortization	(30,742)	(28,125)
Agreements, contracts, and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	11,283	11,267
Accumulated Amortization	(2,961)	(2,449)
Net	8,322	8,818
Accumulated Amortization	$ (2,961)	$ (2,449)

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Accrued professional liabilities	$ 14,319	$ 14,362
Contingent purchase price payable	5,509	5,509
Current income taxes payable	1,782	7,892
Refunds payable	45,175	48,415
Other	35,076	43,059
Total other accrued liabilities	$ 101,861	$ 119,237

Accrued Professional Liabilit49

Accrued Professional Liabilities - Components of Reserves (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Estimated losses under self-insured programs	$ 30,227	$ 30,748
Incurred but not reported losses	33,318	36,166
Total accrued professional liabilities	63,545	66,914
Less estimated losses payable within one year	14,319	14,362
Total	$ 49,226	$ 52,552

Accrued Professional Liabilit50

Accrued Professional Liabilities - Rollforward of Reserves (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Self Insurance Reserve [Roll Forward]
Balance at December 31, 2015	$ 66,914
Provision related to current period reserves	4,274
Payments for prior period reserves	(4,128)
Other, net including post acquisition adjustments	(3,515)
Balance at March 31, 2016	$ 63,545

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($) $ in Thousands	Jul. 16, 2014	Mar. 31, 2016	Dec. 31, 2015	Oct. 21, 2015	Nov. 20, 2012
Revolving Credit Facility [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		$ 155,000	$ 175,000
Term Loan and Credit Facility
Line of Credit Facility, Remaining Borrowing Capacity		$ 345,000
Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 870,000
Quarterly principal payment as a percent of face amount	0.25%
Annual principal payment	$ 8,700
Senior Secured Credit Facility - Term Loan [Member] | Base Rate [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Senior Secured Credit Facility - Term Loan [Member] | Base Rate [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
Senior Secured Credit Facility - Term Loan [Member] | LIBOR [Member]
Term Loan and Credit Facility
Floor rate	0.75%
Current variable rate		3.50%
Senior Secured Credit Facility - Term Loan [Member] | LIBOR [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
Senior Secured Credit Facility - Term Loan [Member] | LIBOR [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%
Revolving Credit Facility [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 500,000			$ 500,000
Increase to borrowing capacity from exercise of accordion feature				$ 200,000
Unused capacity commitment fee, percentage	0.375%
Revolving Credit Facility [Member] | Base Rate [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Revolving Credit Facility [Member] | Base Rate [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
Revolving Credit Facility [Member] | LIBOR [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
Revolving Credit Facility [Member] | LIBOR [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%
Fixed Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		$ 1,390,600
Long-term Debt, Fair Value		1,434,500
Variable Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt, Fair Value		1,011,000
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		250,000	250,000
Senior Unsecured Debt
Face amount					$ 250,000
Interest rate					5.625%
Senior Secured Debt
Face amount					$ 250,000
Interest rate					5.625%
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt		$ 1,100,000	$ 1,100,000
Senior Unsecured Debt
Face amount	$ 1,100,000
Interest rate	5.625%
Redeemable principal percentage		35.00%
Senior Secured Debt
Face amount	$ 1,100,000
Interest rate	5.625%
5.625% Senior Unsecured Notes due 2022 [Member] | Period Prior to July 15, 2017 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount		105.625%

Long-Term Debt (Components Of L

Long-Term Debt (Components Of Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Other debt due through 2025	$ 23,525	$ 24,944
Capitalized lease arrangements due through 2026	18,262	18,613
Long-term debt and capitalized lease arrangements	2,401,562	2,425,507
Less current portion	20,231	20,377
Deferred Finance Costs, Noncurrent, Net	45,047	47,174
Long-term debt	2,336,284	2,357,956
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term Debt	155,000	175,000
Term Loan [Member]
Debt Instrument [Line Items]
Long-term Debt	854,775	856,950
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	250,000	250,000
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 1,100,000	$ 1,100,000

Long-Term Debt (Redemption Pric

Long-Term Debt (Redemption Price) (Details) - Senior Notes [Member]	3 Months Ended
	Mar. 31, 2016
2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	104.219%
2016 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	102.813%
2017 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	101.406%
2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	104.219%
2018 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	100.00%
2018 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	102.813%
2019 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	101.406%
2020 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	100.00%

Other Long-Term Liabilities (De

Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Other Long-Term Liabilities [Abstract]
Accrued professional liabilities	$ 49,226	$ 52,552
Deferred Rent	21,635	18,958
Tax-effected unrecognized benefits	3,426	3,426
Other	24,720	21,247
Other long-term liabilities	$ 99,007	$ 96,183

Shareholder's Equity (Narrative

Shareholder's Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2016USD ($)installment$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares
Common Stock:
Repurchase of common stock, shares		77,780	67,000
Repurchase of common stock | $		$ 5,700	$ 3,700
Mandatory Convertible Preferred Stock
Preferred stock dividends | $		$ (2,264)	$ (2,264)
Preferred Stock, Shares Outstanding	1,725,000	1,725,000
Stock Incentive Plans:
Number of shares authorized for grant under share incentive plan		1,200,000
Shares available for future grants/issuance under stock incentive plan		416,463
Unrecognized compensation cost on non vested awards | $		$ 49,100
Weighted average period		1 year 3 months
Number of units granted		566,763
Grant date value of common stock | $ / shares		$ 73.98
Stock Options [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Options term		10 years
Employees [Member] | Restricted Stock [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Number of installments in restricted stock granted. | installment		3
Mandatory Convertible Preferred Stock [Member]
Stock Incentive Plans:
Number of anti-dilutive options		3,100,000	3,200,000
Stock Options [Member]
Stock Incentive Plans:
Number of anti-dilutive options		0	0
Common Stock [Member]
Issuance of stock (in shares)	5,835,000
Issuance of stock, price per share | $ / shares	$ 80
Stock offering expenses | $	$ 19,100
Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Dividend rate		5.25%
Initial liquidation preference (usd per share) | $ / shares		$ 100
Consecutive trading day		20 days
Dividends declared (usd per share) | $ / shares		$ 1.3125	$ 1.3125
Minimum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate		1.8141
Maximum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate		2.2222
Performance-based Restricted Stock Units [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Number of units granted		73,003
Grant date value of common stock | $ / shares		$ 73.98
Performance goal period for vesting		1 year
Projected vesting percentage		100.00%
Performance-based Restricted Stock Units [Member] | Minimum [Member]
Stock Incentive Plans:
Projected vesting percentage		0.00%
Performance-based Restricted Stock Units [Member] | Maximum [Member]
Stock Incentive Plans:
Projected vesting percentage		150.00%

Shareholders' Equity (Share-Bas

Shareholders' Equity (Share-Based Activity) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Equity [Abstract]
Share-based compensation expense	$ 7,168	$ 3,709
Fair value of shares vested	16,961	11,474
Cash received from option exercises	276	1,746
Tax benefit from exercises of share-based awards	$ 3,605	$ 3,317

Shareholders Equity (Schedule O

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares at beginning of period, Number of Shares | shares	734,101
Shares granted, Number of Shares | shares	566,763
Shares vested, Number of Shares | shares	(231,862)
Shares forfeited, Number of Shares | shares	(5,407)
Non-vested shares at end of period, Number of Shares | shares	1,063,595
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares at beginning of period, Weighted Average Grant Price | $ / shares	$ 44.73
Shares granted, Weighted Average Grant Price | $ / shares	73.98
Shares vested, Weighted Average Grant Price | $ / shares	36.27
Shares forfeited, Weighted Average Grant Price | $ / shares	55.40
Non-vested shares at end of period, Weighted Average Grant Price | $ / shares	$ 62.11

Shareholder's Equity (Schedule

Shareholder's Equity (Schedule of Stock Option Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, Number of Shares	33,751
Options exercised, Number of Shares	(12,667)
Options terminated, Number of Shares	(4,200)
Outstanding at end of period, Number of Shares	16,884	33,751
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period, Weighted Average Exercise Price	$ 22.98
Options exercised, Weighted Average Exercise Price	21.78
Options terminated, Weighted Average Exercise Price	21.07
Outstanding at end of period, Weighted Average Exercise Price	$ 24.36	$ 22.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period, Weighted Average Remaining Contractual Life (in years)	292 days	1 year 36 days
Outstanding at end of period, Weighted Average Remaining Contractual Life (in years)	292 days	1 year 36 days

Shareholder's Equity (Schedul59

Shareholder's Equity (Schedule of Stock Option Activity-Additional) (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Equity [Abstract]
Total intrinsic value with options exercised	$ 0.6
Aggregate intrinsic value of options outstanding	0.9
Total intrinsic value of options vested or expected to vest	$ 0.9
Vested or expected to vest at end of period, Number of Shares | shares	16,884
Vested or expected to vest at end of period, weighted average exercise price | $ / shares	$ 24.36
Vested or expected to vest at end of period, Weighted Average Remaining Contractual Life (in years)	292 days
Total Intrinsic value of options exercisable	$ 0.9
Exercisable at end of period, Number of Shares | shares	16,884
Exercisable at end of period, Weighted Average Exercise Price | $ / shares	$ 24.36
Exercisable at end of period, Weighted Average Remaining Contractual Life (in years)	292 days

Shareholder's Equity (Schedul60

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (Numerator)	$ 28,599	$ 18,774
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (basic), shares (Denominator)	53,665	47,572
Effect of dilutive securities, options and non-vested shares	336	333
Net Income (Loss) Attributable to Parent, Diluted	$ 28,599	$ 18,774
Net earnings (loss) from continuing operations attributable to AmSurg Corp. (diluted), shares (Denominator)	54,001	47,905
Mandatory Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive shares	3,100	3,200

Commitments and Contingencies (

Commitments and Contingencies (Details) ft² in Thousands, $ in Millions	Jan. 16, 2015USD ($)ft²	Mar. 31, 2017ft²	Dec. 31, 2016ft²
Schedule Of Operating Leases Square Footage [Line Items]
Lease square footage	222
Annual rent expense | $	$ 2.9
Scenario, Forecast [Member]
Schedule Of Operating Leases Square Footage [Line Items]
Lease square footage		55	167

Segment Reporting (Details)

Segment Reporting (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)segment	Mar. 31, 2015USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	2
Segment Reporting Information [Line Items]
Net revenue	$ 724,678	$ 570,445
Adjusted EBITDA	120,100	93,755
Earnings from continuing operations attributable to noncontrolling interests	53,841	47,717
Interest expense, net	(30,810)	(30,247)
Depreciation and amortization	(29,072)	(22,818)
Share-based compensation	(7,168)	(3,709)
Transaction costs	(1,390)	(1,471)
Net loss on deconsolidation	0	(223)
Earnings before income taxes	105,501	83,004
Acquisition and Capital Expenditures	18,681	141,361
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Net revenue	307,134	283,910
Adjusted EBITDA	53,626	47,308
Acquisition and Capital Expenditures	8,371	54,096
Physician Services [Member]
Segment Reporting Information [Line Items]
Net revenue	417,544	286,535
Adjusted EBITDA	66,474	46,447
Acquisition and Capital Expenditures	$ 10,310	$ 87,265

Financial Information for the63

Financial Information for the Company and Its Subsidiaries (Balance Sheets) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 85,883	$ 106,660	$ 116,156	$ 208,079
Restricted cash and marketable securities	14,435	13,506
Accounts receivable, net	352,891	337,330
Supplies inventory	21,584	21,406
Prepaid and other current assets	76,513	75,771
Total current assets	551,306	554,673
Property and equipment, net	191,920	189,168
Investments in and receivables from unconsolidated affiliates	172,826	169,170
Goodwill	3,967,902	3,970,210
Intangible assets, net	1,580,337	1,594,637
Other assets	19,655	21,450
Total assets	6,483,946	6,499,308
Liabilities and Equity
Current portion of long-term debt	20,231	20,377
Accounts payable	26,412	32,561
Accrued salaries and benefits	204,191	202,537
Accrued interest	18,005	30,480
Other accrued liabilities	101,861	119,237
Total current liabilities	370,700	405,192
Long-term debt	2,336,284	2,357,956
Deferred income taxes	706,452	699,498
Other long-term liabilities	99,007	96,183
Intercompany payable	0	0
Noncontrolling interests – redeemable	174,671	175,732
Equity:
Total AmSurg Corp. equity	2,326,521	2,293,463
Noncontrolling interests – non-redeemable	470,311	471,284
Total equity	2,796,832	2,764,747
Total liabilities and equity	6,483,946	6,499,308
Consolidation, Eliminations [Member]
Assets
Cash and cash equivalents	0	0	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	(23,349)	(8,076)
Total current assets	(23,349)	(8,076)
Property and equipment, net	0	0
Investments in and receivables from unconsolidated affiliates	(6,503,372)	(6,507,128)
Goodwill	2,013,435	2,013,469
Intangible assets, net	0	0
Other assets	(1,998)	(1,998)
Total assets	(4,515,284)	(4,503,733)
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	(4,087)	(3,852)
Accrued salaries and benefits	0	0
Accrued interest	0	0
Other accrued liabilities	(19,262)	(4,224)
Total current liabilities	(23,349)	(8,076)
Long-term debt	(24,375)	(23,396)
Deferred income taxes	(1,998)	(1,998)
Other long-term liabilities	0	0
Intercompany payable	(1,228,157)	(1,228,157)
Noncontrolling interests – redeemable	113,094	112,672
Equity:
Total AmSurg Corp. equity	(3,774,653)	(3,778,478)
Noncontrolling interests – non-redeemable	424,154	423,700
Total equity	(3,350,499)	(3,354,778)
Total liabilities and equity	(4,515,284)	(4,503,733)
Parent Company [Member]
Assets
Cash and cash equivalents	9,391	20,437	30,118	134,351
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	39,908	28,739
Total current assets	49,299	49,176
Property and equipment, net	12,421	12,515
Investments in and receivables from unconsolidated affiliates	4,901,556	4,901,026
Goodwill	0	0
Intangible assets, net	13,142	12,780
Other assets	4,532	4,653
Total assets	4,980,950	4,980,150
Liabilities and Equity
Current portion of long-term debt	8,700	8,700
Accounts payable	2,196	2,816
Accrued salaries and benefits	25,225	31,510
Accrued interest	17,995	30,463
Other accrued liabilities	8,125	13,962
Total current liabilities	62,241	87,451
Long-term debt	2,306,032	2,326,103
Deferred income taxes	281,498	268,573
Other long-term liabilities	4,658	4,560
Intercompany payable	0	0
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	2,326,521	2,293,463
Noncontrolling interests – non-redeemable	0	0
Total equity	2,326,521	2,293,463
Total liabilities and equity	4,980,950	4,980,150
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	20,632	27,507	38,681	23,471
Restricted cash and marketable securities	995	0
Accounts receivable, net	240,265	223,434
Supplies inventory	0	0
Prepaid and other current assets	31,317	39,046
Total current assets	293,209	289,987
Property and equipment, net	17,824	14,601
Investments in and receivables from unconsolidated affiliates	1,774,642	1,775,272
Goodwill	1,954,467	1,956,741
Intangible assets, net	1,565,068	1,579,537
Other assets	1,583	1,717
Total assets	5,606,793	5,617,855
Liabilities and Equity
Current portion of long-term debt	19	0
Accounts payable	2,080	3,760
Accrued salaries and benefits	162,396	158,705
Accrued interest	0	0
Other accrued liabilities	67,058	76,590
Total current liabilities	231,553	239,055
Long-term debt	40	0
Deferred income taxes	426,952	432,923
Other long-term liabilities	73,729	71,509
Intercompany payable	1,228,157	1,228,157
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	3,646,362	3,646,211
Noncontrolling interests – non-redeemable	0	0
Total equity	3,646,362	3,646,211
Total liabilities and equity	5,606,793	5,617,855
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	55,860	58,716	$ 47,357	$ 50,257
Restricted cash and marketable securities	13,440	13,506
Accounts receivable, net	112,626	113,896
Supplies inventory	21,584	21,406
Prepaid and other current assets	28,637	16,062
Total current assets	232,147	223,586
Property and equipment, net	161,675	162,052
Investments in and receivables from unconsolidated affiliates	0	0
Goodwill	0	0
Intangible assets, net	2,127	2,320
Other assets	15,538	17,078
Total assets	411,487	405,036
Liabilities and Equity
Current portion of long-term debt	11,512	11,677
Accounts payable	26,223	29,837
Accrued salaries and benefits	16,570	12,322
Accrued interest	10	17
Other accrued liabilities	45,940	32,909
Total current liabilities	100,255	86,762
Long-term debt	54,587	55,249
Deferred income taxes	0	0
Other long-term liabilities	20,620	20,114
Intercompany payable	0	0
Noncontrolling interests – redeemable	61,577	63,060
Equity:
Total AmSurg Corp. equity	128,291	132,267
Noncontrolling interests – non-redeemable	46,157	47,584
Total equity	174,448	179,851
Total liabilities and equity	$ 411,487	$ 405,036

Financial Information for the64

Financial Information for the Company and Its Subsidiaries (Income Statements) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Net revenue	$ 724,678	$ 570,445
Operating expenses:
Salaries and benefits	409,839	302,179
Supply cost	46,963	42,584
Other operating expenses	107,682	90,570
Transaction costs	1,390	1,471
Depreciation and amortization	29,072	22,818
Total operating expenses	594,946	459,622
Net loss on deconsolidations	0	(223)
Equity in earnings of unconsolidated affiliates	6,579	2,651
Operating income	136,311	113,251
Interest expense (income), net	30,810	30,247
Earnings before income taxes	105,501	83,004
Income tax expense	20,797	14,249
Net earnings	84,704	68,755
Less net earnings attributable to noncontrolling interests	53,841	47,717
Net earnings attributable to AmSurg Corp. shareholders	30,863	21,038
Preferred stock dividends	(2,264)	(2,264)
Net earnings attributable to AmSurg Corp. common shareholders	28,599	18,774
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	(10,308)	(8,854)
Operating expenses:
Salaries and benefits	(133)	(128)
Supply cost	(13)	0
Other operating expenses	(10,162)	(8,726)
Transaction costs	0	0
Depreciation and amortization	0	0
Total operating expenses	(10,308)	(8,854)
Net loss on deconsolidations		188
Equity in earnings of unconsolidated affiliates	(127,899)	(112,319)
Operating income	(127,899)	(112,131)
Interest expense (income), net	0	0
Earnings before income taxes	(127,899)	(112,131)
Income tax expense	0	0
Net earnings	(127,899)	(112,131)
Less net earnings attributable to noncontrolling interests	0	0
Net earnings attributable to AmSurg Corp. shareholders	(127,899)	(112,131)
Preferred stock dividends	0	0
Net earnings attributable to AmSurg Corp. common shareholders	(127,899)	(112,131)
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	8,544	7,091
Operating expenses:
Salaries and benefits	24,095	17,643
Supply cost	0	0
Other operating expenses	7,618	6,634
Transaction costs	177	268
Depreciation and amortization	1,072	834
Total operating expenses	32,962	25,379
Net loss on deconsolidations		(188)
Equity in earnings of unconsolidated affiliates	69,042	60,387
Operating income	44,624	41,911
Interest expense (income), net	(2,819)	11,886
Earnings before income taxes	47,443	30,025
Income tax expense	16,580	8,987
Net earnings	30,863	21,038
Less net earnings attributable to noncontrolling interests	0	0
Net earnings attributable to AmSurg Corp. shareholders	30,863	21,038
Preferred stock dividends	(2,264)	(2,264)
Net earnings attributable to AmSurg Corp. common shareholders	28,599	18,774
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	415,830	285,579
Operating expenses:
Salaries and benefits	309,580	211,601
Supply cost	1,007	396
Other operating expenses	43,339	29,611
Transaction costs	1,213	1,203
Depreciation and amortization	20,336	14,307
Total operating expenses	375,475	257,118
Net loss on deconsolidations		(188)
Equity in earnings of unconsolidated affiliates	65,436	54,583
Operating income	105,791	82,856
Interest expense (income), net	32,976	17,754
Earnings before income taxes	72,815	65,102
Income tax expense	3,774	4,903
Net earnings	69,041	60,199
Less net earnings attributable to noncontrolling interests	0	0
Net earnings attributable to AmSurg Corp. shareholders	69,041	60,199
Preferred stock dividends	0	0
Net earnings attributable to AmSurg Corp. common shareholders	69,041	60,199
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue	310,612	286,629
Operating expenses:
Salaries and benefits	76,297	73,063
Supply cost	45,969	42,188
Other operating expenses	66,887	63,051
Transaction costs	0	0
Depreciation and amortization	7,664	7,677
Total operating expenses	196,817	185,979
Net loss on deconsolidations		(35)
Equity in earnings of unconsolidated affiliates	0	0
Operating income	113,795	100,615
Interest expense (income), net	653	607
Earnings before income taxes	113,142	100,008
Income tax expense	443	359
Net earnings	112,699	99,649
Less net earnings attributable to noncontrolling interests	53,841	47,717
Net earnings attributable to AmSurg Corp. shareholders	58,858	51,932
Preferred stock dividends	0	0
Net earnings attributable to AmSurg Corp. common shareholders	$ 58,858	$ 51,932

Financial Information for the65

Financial Information for the Company and Its Subsidiaries (Cash Flow Statements) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net cash flows provided by operating activities	$ 81,773	$ 98,827
Cash flows from investing activities:
Acquisitions and related expenses	(2,990)	(126,578)
Acquisition of property and equipment	(15,691)	(14,783)
Maturities of marketable securities	2,240	0
Other	(1,509)	(220)
Net cash flows used in investing activities	(17,950)	(141,581)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	16,197	2,227
Repayment on long-term borrowings and revolving credit facility	(40,332)	(5,213)
Distributions to owners, including noncontrolling interests	(56,801)	(47,202)
Capital contributions		0
Changes in intercompany balances with affiliates, net	0	0
Other, net	(3,664)	1,019
Net cash flows used in financing activities	(84,600)	(49,169)
Net decrease in cash and cash equivalents	(20,777)	(91,923)
Cash and cash equivalents, beginning of period	106,660	208,079
Cash and cash equivalents, end of period	85,883	116,156
Consolidation, Eliminations [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	(131,699)	(62,196)
Cash flows from investing activities:
Acquisitions and related expenses	0	62,525
Acquisition of property and equipment	0	0
Maturities of marketable securities	0
Other	0	0
Net cash flows used in investing activities	0	62,525
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0
Repayment on long-term borrowings and revolving credit facility	0	0
Distributions to owners, including noncontrolling interests	131,699	62,196
Capital contributions		(62,056)
Changes in intercompany balances with affiliates, net	0	0
Other, net	0	(469)
Net cash flows used in financing activities	131,699	(329)
Net decrease in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	18,122	(33,779)
Cash flows from investing activities:
Acquisitions and related expenses	0	(62,056)
Acquisition of property and equipment	(1,509)	(2,678)
Maturities of marketable securities	0
Other	0	0
Net cash flows used in investing activities	(1,509)	(64,734)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	15,000	0
Repayment on long-term borrowings and revolving credit facility	(37,175)	(2,175)
Distributions to owners, including noncontrolling interests	0	0
Capital contributions		0
Changes in intercompany balances with affiliates, net	(979)	(2,573)
Other, net	(4,505)	(972)
Net cash flows used in financing activities	(27,659)	(5,720)
Net decrease in cash and cash equivalents	(11,046)	(104,233)
Cash and cash equivalents, beginning of period	20,437	134,351
Cash and cash equivalents, end of period	9,391	30,118
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	72,860	91,981
Cash flows from investing activities:
Acquisitions and related expenses	(2,990)	(127,047)
Acquisition of property and equipment	(7,320)	(2,538)
Maturities of marketable securities	0
Other	(878)	(1,322)
Net cash flows used in investing activities	(11,188)	(130,907)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0
Repayment on long-term borrowings and revolving credit facility	0	0
Distributions to owners, including noncontrolling interests	(68,547)	(10,241)
Capital contributions		62,056
Changes in intercompany balances with affiliates, net	0	0
Other, net	0	2,321
Net cash flows used in financing activities	(68,547)	54,136
Net decrease in cash and cash equivalents	(6,875)	15,210
Cash and cash equivalents, beginning of period	27,507	23,471
Cash and cash equivalents, end of period	20,632	38,681
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	122,490	102,821
Cash flows from investing activities:
Acquisitions and related expenses	0	0
Acquisition of property and equipment	(6,862)	(9,567)
Maturities of marketable securities	2,240
Other	(631)	1,102
Net cash flows used in investing activities	(5,253)	(8,465)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	1,197	2,227
Repayment on long-term borrowings and revolving credit facility	(3,157)	(3,038)
Distributions to owners, including noncontrolling interests	(119,953)	(99,157)
Capital contributions		0
Changes in intercompany balances with affiliates, net	979	2,573
Other, net	841	139
Net cash flows used in financing activities	(120,093)	(97,256)
Net decrease in cash and cash equivalents	(2,856)	(2,900)
Cash and cash equivalents, beginning of period	58,716	50,257
Cash and cash equivalents, end of period	$ 55,860	$ 47,357